View Clinical Trial (Medical Research Study)

Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM) - NCT00856323-90028(Clinical Trial 276005)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Los Angeles
State:  
CA
Zip Code: 90028
Conditions: Amphetamine-Related Disorders - HIV - HIV Infections
Purpose: This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors among methamphetamine-using men who have sex with men (MSM) by combining a biomedical intervention with a behavioral intervention. The behavioral intervention will consist of an 8-week course of contingency management (CM) through which participants will be reinforced for testing negative for methamphetamine metabolites during periodic urine analyses. The biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be administered after an unanticipated HIV risk exposure (i.e., engaging in either receptive or insertive anal sex without a condom with someone who is HIV-positive or of unknown status). In combining these two interventions, this study seeks to evaluate the combined intervention's effects on sexual risk behaviors and methamphetamine use.
Study summary:
Criteria: Inclusion Criteria: - Individual must identify as a male who has sex with other men (MSM); - At least 18 years of age; - HIV negative serostatus on baseline rapid oral HIV antibody test; - Self-reported methamphetamine use within the previous 72 hours and test positive for methamphetamine metabolites at baseline; - Self-reported unprotected anal intercourse (either receptive or insertive) with an HIV-positive or status unknown partner within the previous 3 months; - Self-reports no previous hypersensitivity to any of the components of Truvada (tenofovir disoproxil fumarate or emtricitabine); - Willing to comply with study requirements (i.e., monitored urine testing three times per week, meet with physician within first week of enrollment, begin medication immediately following an unexpected high-risk sexual exposure, and contact the clinic and meet with physician within 92 hours of unexpected high-risk sexual exposure). Exclusion Criteria: - Does not identify as a male who has sex with other men; - Under 18 years of age; - HIV positive, by self-report or as indicated by the results on the baseline rapid oral HIV antibody test; - Self-reports any previous hypersensitivity to any of the components of Truvada; - Has not used methamphetamine in the previous 72 hours and does not test positive for methamphetamine metabolites; - Has not had unprotected anal intercourse with an HIV-positive or status unknown partner within the previous 3 months; - Unwilling to comply with study requirements.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 17, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.